Citations

Showing 10 of 108162 citations.

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
Menéndez, Javier A. , Papadimitropoulou, Adriana, Steen, Travis Vander, Oza-Gajera, Bharvi P. , Verdura, Sara , Espinoza, Ingrid , Vellón, Luciano , Lupu, Ruth , Vander Steen, Travis, Verdura, Sara , Menendez, Javier A , Cuyàs, Elisabet , Mehmi, Inderjit

Mayo Clinic

Cancers | March 7, 2021 | Volume: 13 | Issue: 5 | Pages: 1132

10.3390/cancers13051132 | PMID 33800852 Get It

The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor receptors such as human epidermal growth factor receptor 2 (HER2) has frequently been associated with both experimental and clinical endocrine therapy resistance, combined targeting of ER and HER2 has failed to improve overall survival in endocrine non-responsive disease. Herein, we questioned the role of fatty acid synthase (FASN), a lipogenic enzyme linked to HER2-driven breast cancer aggressiveness, in the development and maintenance of hormone-independent growth and resistance to anti-estrogens in ER/HER2-positive (ER+/HER2+) breast cancer. The stimulatory effects of estradiol on FASN gene promoter activity and protein expression were blunted by anti-estrogens in endocrine-responsive breast cancer cells. Conversely, an AKT/MAPK-related constitutive hyperactivation of FASN gene promoter activity was unaltered in response to estradiol in non-endocrine responsive ER+/HER2+ breast cancer cells, and could be further enhanced by tamoxifen. Pharmacological blockade with structurally and mechanistically unrelated FASN inhibitors fully impeded the strong stimulatory activity of tamoxifen on the soft-agar colony forming capacity—an in vitro metric of tumorigenicity—of ER+/HER2+ breast cancer cells. In vivo treatment with a FASN inhibitor completely prevented the agonistic tumor-promoting activity of tamoxifen and fully restored its estrogen antagonist properties against ER/HER2-positive xenograft tumors in mice. Functional cancer proteomic data from The Cancer Proteome Atlas (TCPA) revealed that the ER+/HER2+ subtype was the highest FASN protein expressor compared to basal-like, HER2-enriched, and ER+/HER2-negative breast cancer groups. FASN is a biological determinant of HER2-driven endocrine resistance in ER+ breast cancer. Next-generation, clinical-grade FASN inhibitors may be therapeutically relevant to countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.
Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie's Disease: A Retrospective Claims Database Analysis
Trost, Landon , Huang, Huan , Burudpakdee, Chakkarin , Hu, Yiqun , Han, Xu

Mayo Clinic

Sexual Medicine | March 7, 2021 | Volume: 9 | Issue: 2 | Pages: 100321-100321

10.1016/j.esxm.2021.100321 | PMID 33684795 Get It

Abstract Introduction Treatments for Peyronie's disease (PD) include surgical management and collagenase clostridium histolyticum (CCH). Aims To evaluate PD treatment trends after CCH approval and compare clinical outcomes in CCH- and surgery-treated cohorts. Methods Patients newly diagnosed with PD between January 2011 and December 2017 were identified in a U.S. claims database. Cohorts initiating treatment with CCH or surgery between January 2014 and June 2017 were included. Patients were continuously enrolled ≥6 months before and ≥12 months after index date. Post-treatment penile complications and analgesic use were compared 1 year after procedure in propensity score-matched cohorts. Main outcome measures The main outcome measures of this study were treatment patterns, penile complications, and analgesic use. Results In the newly diagnosed PD cohort, 1,609 patients received CCH and 1,555 patients had surgery. Overall CCH or surgery treatment rate/year increased from 9.8% in 2014 to 15.5% in 2017, with <1% receiving verapamil or interferon. Initial treatment ratios of CCH to surgery increased from approximately 1:1 (2014) to 2:1 (2017). In the unmatched CCH (n = 1,227) and surgery (n = 620) cohorts, more (P < .05) surgery-treated patients received analgesics (particularly opioids), oral PD therapies, vacuum erection devices, and phosphodiesterase-5 inhibitors before the index date. After propensity score matching (n = 620/cohort), newly occurring postprocedural complications during the follow-up period were higher in the surgery cohort (25.3% vs 18.4%, P = .003). The surgery cohort had significantly (P < .05) higher rates of erectile dysfunction (65.0% vs 44.8%), penile pain (17.9% vs 8.9%), and penile swelling (8.1% vs 5.2%) and was more likely to be prescribed opioids (93.3% vs 38.9%; P < .0001) or non-steroidal anti-inflammatory drugs (27.0% vs 20.3%; P = .006). Conclusion CCH demonstrated fewer complications and less analgesic use than surgery and was used as the initial therapy for PD twice as often as surgery.
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson, Gabriella , John, Binu V. , John, Binu V , Mahipal, Amit

Mayo Clinic

Expert Opinion on Investigational Drugs | March 6, 2021 | Volume: 30 | Issue: 4 | Pages: 463-477

10.1080/13543784.2021.1900821 | PMID 33678096 Get It

Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation
Duarte-Rojo, Andres, Heimbach, Julie K., Borja-Cacho, Daniel, Barone, Gary W., Shaheen, Mohammed F., Lamps, Laura W., Graham, Rondell P., Tan, Ek Khoon, Concepcion, Waldo, Kim, W. Ray, Graham, Rondell P. , Kim, W. Ray , Tan, Ek Khoon , Duarte‐Rojo, Andrés , Graham, Rondell P , Duarte-Rojo, Andres , Heimbach, Julie K., Borja-Cacho, Daniel, Barone, Gary W., Shaheen, Mohammed F., Lamps, Laura W., Graham, Rondell P., Tan, Ek Khoon, Concepcion, Waldo, Kim, W. Ray

Mayo Clinic

Transplantation | March 6, 2021 | Volume: 106 | Issue: 2 | Pages: 318-327

10.1097/tp.0000000000003720 | PMID 33675319 Get It

Background. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) are noninvasive surrogates for hepatic steatosis and fibrosis, respectively, and could help identify extended criteria donors in liver transplantation (LT). We aimed to determine the accuracy of CAP/LSM in deceased donors along with post-LT changes. Methods. Accuracy of preprocurement CAP/LSM to grade/stage steatosis/fibrosis was determined using liver biopsy as reference. Transplant outcomes, including primary nonfunction (PNF) and early allograft dysfunction, were recorded. Recipients underwent CAP/LSM as outpatients. Areas under the receiver operating characteristic curve and regression models were constructed to analyze data. Results. We prospectively evaluated 160 allografts (138 transplanted). Same-probe paired baseline/post-LT CAP was 231 dB/m (181–277)/225 (187–261) (P = 0.61), and LSM 7.6 kPa (6.3–10.8)/5.9 (4.6–8.7) (P = 0.002), respectively. CAP reading was affected by BMI and LSM by ALT, race and bilirubin. Although CAP did not correlate with steatosis from frozen sections (ρ = 0.08, P = 0.47), it correlated with steatosis from permanent sections (ρ = 0.32, P < 0.001) and with oil red O histomorphometry (ρ = 0.35, P = 0.001). CAP identified moderate-to-severe steatosis with an areas under the receiver operating characteristic curve curve of 0.79 (0.66–0.91), for a negative predictive value of 100% at a cutoff value of 230 dB/m. LSM correlated with fibrosis staging (ρ = 0.22, P = 0.007) and it identified discarded allografts with advanced fibrosis/cirrhosis. Patients with no to minimal fibrosis had an LSM of 7.6 (6–10.1) kPa. Conclusions. Our results are proof-of-concept of the utility of CAP/LSM during organ procurement. Establishing the precise role of these noninvasive tools in the organ allocation process mandates confirmatory studies.
Risk Prediction for Delayed Allograft Function: Analysis of the Deterioration of Kidney Allograft Function (DeKAF) Study Data
Matas, Arthur J. , Fieberg, Ann, Leduc, Robert, Gaston, Robert S. , Kasiske, Bertram L. , Hunsicker, Lawrence, Cosio, Fernando, Grande, Joseph P. , Cecka, J. Michael, Connett, John E. , Mannon, Roslyn B. , Mannon, Roslyn B , Helgeson, Erika S. , Rush, David N. , Hunsicker, Lawrence

Mayo Clinic

Transplantation | March 6, 2021 | Volume: 106 | Issue: 2 | Pages: 358-368

10.1097/tp.0000000000003718 | PMID 33675321 Get It

Background. Delayed graft function (DGF) of a kidney transplant results in increased cost and complexity of management. For clinical care or a DGF trial, it would be ideal to accurately predict individual DGF risk and provide preemptive treatment. A calculator developed by Irish et al has been useful for predicting population but not individual risk. Methods. We analyzed the Irish calculator (IC) in the DeKAF prospective cohort (incidence of DGF = 20.4%) and investigated potential improvements. Results. We found that the predictive performance of the calculator in those meeting Irish inclusion criteria was comparable with that reported by Irish et al. For cohorts excluded by Irish: (a) in pump-perfused kidneys, the IC overestimated DGF risk; (b) in simultaneous pancreas kidney transplants, the DGF risk was exceptionally low. For all 3 cohorts, there was considerable overlap in IC scores between those with and those without DGF. Using a modified definition of DGF—excluding those with single dialysis in the first 24 h posttransplant—we found that the calculator had similar performance as with the traditional DGF definition. Studying whether DGF prediction could be improved, we found that recipient cardiovascular disease was strongly associated with DGF even after accounting for IC-predicted risk. Conclusions. The IC can be a useful population guide for predicting DGF in the population for which it was intended but has limited scope in expanded populations (SPK, pump) and for individual risk prediction. DGF risk prediction can be improved by inclusion of recipient cardiovascular disease.
Guidelines for Perioperative Care for Emergency Laparotomy Enhanced Recovery After Surgery (ERAS) Society Recommendations: Part 1—Preoperative: Diagnosis, Rapid Assessment and Optimization
Peden, Carol J. , Aggarwal, Geeta , Aitken, Robert , Anderson, I D , Cooper, Zara , Dhesi, Jugdeep , French, W. Brenton, Hammarqvist, Folke , Hare, Sarah P., Havens, Joaquim M. , Holena, Daniel N. , Hübner, Martin , Kim, Jeniffer S. , Lees, Nicholas P. , Ljungqvist, Olle , Lobo, Dileep N. , Quiney, Nial , Wick, Elizabeth C. , Young‐Fadok, Tonia M., Scott, Michael J. , Cooper, Zara , Aitken, Robert J , Cooper, Zara , Lees, Nicholas P , Lobo, D N , Mohseni, Shahin , Ordoñez, Carlos A , Urman, Richard D , Young-Fadok, Tonia, Scott, M J , Peden, Carol J , Hübner, Martin , Foss, Nicolai Bang , Grant, Michael Conrad , Mohseni, Shahin , Ordóñez, Carlos A. , Wu, Christopher L

Mayo Clinic

World Journal of Surgery | March 6, 2021 | Volume: 45 | Issue: 5 | Pages: 1272-1290

10.1007/s00268-021-05994-9 | PMID 33677649 Get It

Abstract Background Enhanced Recovery After Surgery (ERAS) protocols reduce length of stay, complications and costs for a large number of elective surgical procedures. A similar, structured approach appears to improve outcomes, including mortality, for patients undergoing high‐risk emergency general surgery, and specifically emergency laparotomy. These are the first consensus guidelines for optimal care of these patients using an ERAS approach. Methods Experts in aspects of management of the high‐risk and emergency general surgical patient were invited to contribute by the International ERAS® Society. Pubmed, Cochrane, Embase, and MEDLINE database searches on English language publications were performed for ERAS elements and relevant specific topics. Studies on each item were selected with particular attention to randomized controlled trials, systematic reviews, meta‐analyses and large cohort studies, and reviewed and graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Recommendations were made on the best level of evidence, or extrapolation from studies on non‐emergency patients when appropriate. The Delphi method was used to validate final recommendations. The guideline has been divided into two parts: Part 1—Preoperative Care and Part 2—Intraoperative and Postoperative management. This paper provides guidelines for Part 1. Results Twelve components of preoperative care were considered. Consensus was reached after three rounds. Conclusions These guidelines are based on the best available evidence for an ERAS approach to patients undergoing emergency laparotomy. Initial management is particularly important for patients with sepsis and physiological derangement. These guidelines should be used to improve outcomes for these high‐risk patients.
The EP3662 clone of CD1a supports the diagnosis of New World cutaneous leishmaniasis
Hammond, Alexander M. , Kallis, Penelope , Sokumbi, Olayemi , Auerbach, Jena, Vincek, Vladimir , Kallis, Penelope J , Motaparthi, Kiran , Sokumbi, Olayemi

Mayo Clinic

Journal of Cutaneous Pathology | March 6, 2021 | Volume: 48 | Issue: 10 | Pages: 1317-1320

10.1111/cup.14001 | PMID 33675546 Get It

Beyond Hemoglobin A1c: A Videographic Analysis of Conversations About Quality of Life and Treatment Burden During Clinical Encounters for Diabetes Care
Haider, Shanzay , Kawkgi, Omar El , Clark, Jennifer , Breslin, Maggie , Boehmer, Kasey R. , Montori, Víctor M. , Lipska, Kasia J.

Mayo Clinic

No container title available | March 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-282506/v1 Get It

Abstract Purpose: Diabetes care has largely focused on reducing the risk of complications by achieving hemoglobin A1c (HbA1c) targets; yet, whole-person care may be more effective and desirable. We sought to determine the nature of discussions about quality of life, burden of treatment, hypoglycemia, sexual function, and social support during diabetes-focused clinical encounters.Methods: We analyzed 41 previously recorded clinical encounters with patients with type 2 diabetes from the control arms of practice-based trials of shared decision making. Two coders evaluated videos for discussions about aspects of life with diabetes: quality of life, burden of treatment, hypoglycemia, sexual function, and social supports. When an aspect was raised, coders evaluated the nature of the conversation, clinician responses, and time spent on discussing the aspect. Results: Median length of the encounter was 15 minutes, 6 seconds (IQR: 11:16 – 20:23 minutes). Thirty five of 41 encounters (85.4%), included some discussion of quality of life (58.5%), burden of treatment (51.2%), social support (2.4%), or hypoglycemia (9.8%). Sexual function was not discussed. On average, 4.5% (1.4%-5.5%) of the encounter time involved conversations about HbA1c whereas 15.0% (0%-25%) of the encounter was spent on some aspect of quality of life, burden of treatment, social support, or hypoglycemia. If a topic related to quality of life was raised, clinicians most often responded by acknowledging patient’s concern without providing a solution (45.8%). Conclusions: A significant part of the patient-clinician encounter involves discussion of quality of life and burden of treatment, but clinicians rarely address these issues by providing solutions.
Quantitative analysis of myokymic discharges in radiation versus nonradiation cases
Oishi, Tatsuya , Ryan, Conor S. , Campo, Rocio Vazquez Do , Laughlin, Ruple S. , Rubin, Devon I., Vazquez Do Campo, Rocio

Mayo Clinic

Muscle & Nerve | March 6, 2021 | Volume: 63 | Issue: 6 | Pages: 861-867

10.1002/mus.27219 | PMID 33675544 Get It

AbstractIntroductionMyokymic discharges are classically associated with nerve injury from prior radiation but may occur in other neuromuscular disorders. Using quantitative analysis we aimed to identify the spectrum of conditions in which myokymic discharges are present and determine if there are electrophysiological features that distinguish postradiation from nonradiation causes of myokymia.MethodsWe reviewed the clinical history of all patients examined in our electromyography labs with myokymic discharges recorded from June 2017 to February 2020. Quantitative analysis of each myokymic discharge was performed using a custom MATLAB script, assessing features such as burst frequency, spikes per burst, and burst regularity.ResultsEighty‐eight distinct myokymic discharges (70 patients) were analyzed: 51 postradiation recordings from 35 patients and 37 recordings from 35 nonradiation patients. The diagnostic spectrum of nonradiation cases was diverse, with common causes being median neuropathy (n = 8), cervical (n = 7), and lumbar (n = 5) radiculopathy, and motor neuron disease (n = 5). On quantitative analysis, postradiation myokymia had an increased burst‐to‐silence ratio (median, 0.29; nonradiation, 0.08) and greater peak number (median, 15; nonradiation, 7). Except for one patient with hereditary peripheral nerve hyperexcitability, all patients who had two or more muscles demonstrating myokymic discharges belonged to postradiation group.ConclusionsMyokymic discharges can be seen in diverse neuromuscular conditions; most common in our cohort was chronic median neuropathy. Postradiation myokymia appears to have distinguishing morphological features when quantitatively analyzed compared with nonradiation cases.
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
Macauda, Angelica , Piredda, Chiara , Clay‐Gilmour, Alyssa , Sáinz, Juan , Buda, Gabriele , Markiewicz, Mirosław , Barington, Torben , Ziv, Elad , Hildebrandt, Michelle A.T. , Belachew, Alem A. , Várkonyi, Judit , Prejzner, Witold , Druzd‐Sitek, Agnieszka , Spinelli, John J. , Andersen, Niels Frost, Dudziński, Marek , Martínez‐López, Joaquín , Iskierka‐Jazdzewska, Elżbieta , Mazur, Grzegorz , Ebbesen, Lene Hyldahl, Rymko, Marcin , Subocz, Edyta , Reis, Rui Manuel , García‐Sánz, Ramón , Suska, Anna , Haastrup, Eva, Zawirska, Daria , Grząśko, Norbert , Kruszewski, Marcin , Dutka, Magdalena , Camp, Nicola J. , Waller, Rosalie, Pelosini, Matteo , Raźny, Małgorzata , Abildgaard, Niels , Wątek, Marzena , Brown, Elizabeth E. , Berndt, Sonja I. , Butrym, Aleksandra , Vachon, Celine M. , Gemignani, Federica , Campa, Daniele , Martinez-Lopez, Joaquin , Waller, Rosalie G. , Griffin, R. L. , Canzian, Federico , Campa, Daniele , Martinez-Lopez, Joaquin , Butrym, Aleksandra , Reis, Rui Manuel , Garcia-Sanz, Ramon , Ziv, Elad , Waller, Rosalie G , Rymko, Marcin , Subocz, Edyta , Tomczak, Waldemar , Sainz, Juan , Watek, Marzena , Iskierka-Jazdzewska, Elżbieta , Martinez-Lopez, Joaquin , Mazur, Grzegorz , Hildebrandt, Michelle A T , Markiewicz, Miroslaw , Macauda, Angelica , Griffin, Rosalie , Hofmann, Jonathan N. , Milne, Roger L. , Giles, Graham G. , Jamroziak, Krzysztof , Vangsted, Annette Juul , Dumontet, Charles , Tomczak, Waldemar , Marques, Herlander , Jurczyszyn, Artur , Vachon, Celine M. , Norman, Aaron D. , Slager, Susan L. , Canzian, Federico

Mayo Clinic

International Journal of Cancer | March 6, 2021 | Volume: 149 | Issue: 2 | Pages: 327-336

10.1002/ijc.33547 | PMID 33675538 Get It

AbstractGene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype‐tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10−7 either in EBV‐transformed B‐lymphocytes or whole blood. We genotyped the resulting 22 SNPs in 1327 MM cases from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and examined their association with overall survival (OS) and progression‐free survival (PFS), adjusting for age, sex, country of origin and disease stage. Three polymorphisms in two genes (TBRG4‐rs1992292, TBRG4‐rs2287535 and ENTPD1‐rs2153913) showed associations with OS at P < .05, with the former two also associated with PFS. The associations of two polymorphisms in TBRG4 with OS were replicated in 1277 MM cases from the International Lymphoma Epidemiology (InterLymph) Consortium. A meta‐analysis of the data from IMMEnSE and InterLymph (2579 cases) showed that TBRG4‐rs1992292 is associated with OS (hazard ratio = 1.14, 95% confidence interval 1.04‐1.26, P = .007). In conclusion, we found biologically a plausible association between a SNP in TBRG4 and OS of MM patients.